Recursion Pharmaceuticals (RXRX): Evaluating Valuation After Fresh Leadership, Pharma Partnerships, and Market Optimism
Simply Wall St 24/11 01:12
AEterna Zentaris Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY
COSCIENS Biopharma Inc. - Common Stock CSCI | 0.00 |
